Tags

Type your tag names separated by a space and hit enter

[Therapeutic innovations for hemophilia].
Rev Med Suisse 2020; 16(676-7):47-52RM

Abstract

The current treatment of haemophilia relies on intravenous administration several times a week of clotting factors VIII (FVIII) or IX (FIX) concentrates, either derived from plasma or produced by biotechnology. This preventive treatment is burdensome, expensive and associated with the risk of developing neutralizing antibodies (inhibitors). Factor VIII and IX concentrates with a longer half-life, a bispecific monoclonal antibody mimicking the action of FVIII as well as various strategies modifying the physiological control of coagulation and administered subcutaneously represent new treatment options, validated or being evaluated. The first results of gene therapy studies also seem very promising. These developments offer hemophiliacs patients new perspectives of treatment if not cure that this article proposes to review.

Authors+Show Affiliations

Unité d'hémostase-thrombose, Service d'hématologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Bruxelles.Unité d'hémostase-thrombose, Service d'hématologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Bruxelles.

Pub Type(s)

Journal Article
Review

Language

fre

PubMed ID

31961083

Citation

Hermans, Cedric, and Catherine Lambert. "[Therapeutic Innovations for Hemophilia]." Revue Medicale Suisse, vol. 16, no. 676-7, 2020, pp. 47-52.
Hermans C, Lambert C. [Therapeutic innovations for hemophilia]. Rev Med Suisse. 2020;16(676-7):47-52.
Hermans, C., & Lambert, C. (2020). [Therapeutic innovations for hemophilia]. Revue Medicale Suisse, 16(676-7), pp. 47-52.
Hermans C, Lambert C. [Therapeutic Innovations for Hemophilia]. Rev Med Suisse. 2020 Jan 15;16(676-7):47-52. PubMed PMID: 31961083.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Therapeutic innovations for hemophilia]. AU - Hermans,Cedric, AU - Lambert,Catherine, PY - 2020/1/22/entrez PY - 2020/1/22/pubmed PY - 2020/1/28/medline SP - 47 EP - 52 JF - Revue medicale suisse JO - Rev Med Suisse VL - 16 IS - 676-7 N2 - The current treatment of haemophilia relies on intravenous administration several times a week of clotting factors VIII (FVIII) or IX (FIX) concentrates, either derived from plasma or produced by biotechnology. This preventive treatment is burdensome, expensive and associated with the risk of developing neutralizing antibodies (inhibitors). Factor VIII and IX concentrates with a longer half-life, a bispecific monoclonal antibody mimicking the action of FVIII as well as various strategies modifying the physiological control of coagulation and administered subcutaneously represent new treatment options, validated or being evaluated. The first results of gene therapy studies also seem very promising. These developments offer hemophiliacs patients new perspectives of treatment if not cure that this article proposes to review. SN - 1660-9379 UR - https://www.unboundmedicine.com/medline/citation/31961083/[Therapeutic_innovations_for_hemophilia] L2 - http://www.diseaseinfosearch.org/result/3311 DB - PRIME DP - Unbound Medicine ER -